ESMO26: Lunit SCOPE studies highlight AI-based pathology benefit

Lunit presented results from multiple SCOPE studies at ESMO26 demonstrating the clinical application of its AI-based pathology software across various cancer types. SCOPE is an artificial-intelligence platform designed to assist pathologists in diagnostic analysis. The studies highlight the technology's performance across diverse oncology applications, signaling vendor investment in AI-driven diagnostic tools for the pathology workflow.